Date: 2016-01-19
Type of information: Collaboration agreement
Compound: IMMray™ PanCan-d (blood based test for early detection of pancreatic cancer)
Company: Immunovia (Sweden) the University of Liverpool (UK)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: collaboration
Action mechanism: diagnostic test/biomarker signature. The test is a microchip with a panel of clinically relevant antibodies which is called a biomarker signature. The signature binds with extremely high specificity and sensitivity in a specific pattern the proteins that are present in the blood sample and are associated with the disease. The test can give a clear answer about the presence or absence of the disease in early stages. The technology comes from Professor Carl Borrebaeck and his research team at Create Health Cancer Center.
Disease: pancreatic cancer
Details: * On January 19th, 2016, Immunovia announced that the first European site participating in its prospective clinical study for the early diagnosis of pancreatic cancer will be the National Institute for Health Research (NIHR) Pancreatic Biomedical Research Unit, based at the Royal Liverpool University Hospital. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting in the second half of 2016. The Pancreatic Biomedical Research Unit in Liverpool will contribute together with the other sites to the development of the prospective study clinical protocol. This will involve obtaining the required approvals to recruit study subjects and following them up over a period of three years, delivering the blood samples for analysis and disseminating the results to clinicians and patients. The NIHR Pancreatic Biomedical Research Unit in Liverpool co-ordinates Europe’s biggest registry of individuals at high risk of pancreatic cancer and this collaboration will enable us to take a potentially lifesaving test into the clinic”, said Dr. Bill Greenhalf, Operational Director of Liverpool Good Clinical Laboratory Practice Facility and Lead Scientist of EUROPAC. In addition to the collaboration agreement signed with the University of Liverpool, UK, for the prospective validation of IMMray™ PanCan-d, Immunovia announced a partnership in October with the Knight Cancer Institute at Oregon Health and Sciences University.
Financial terms:
Latest news:
